In gastroenterology, Cannabis extracts are known for their antiemetic, appetitestimulating and antidiarrhoeal effects. Despite the well-characterized influence of cannabinoids in experimental intestinal inflammation, 1 knowledge on the potential benefits of cannabinoids in IBD in humans is largely based on anecdotal reports. Strong evidence from basic science indicates that cannabinoids protect against and alleviate intestinal inflammation in mice, but for IBD in humans the effects of c annabinoids remain to be established in clinical trials. Now, Ravikoff Allegretti et al. 2 have published a prospective survey study on 292 patients with IBD revealing that a substantial number of patients with IBD in the USA use or have used Cannabis (51.3%); 16.4% of all patients had used Cannabis to treat IBD-related symptoms, such as abdominal pain, loss of appetite, nausea and diarrhoea. 2 The majority of the patients reported that Cannabis was "very helpful" in reducing abdominal pain, nausea and diarrhoea. An important aspect of their study was that both patients with Crohn's disease and patients with ulcerative colitis classified Cannabis in general as "very helpful". Using multivariate analysis, the authors identified that age and abdominal pain were the strongest predictors for the use of Cannabis in patients with IBD. Without doubt, the present survey supports the traditional view that Cannabis provides benefit in disturbances of the gastrointestinal tract, e specially in abdominal pain.
The results of the study by Ravikoff Allegretti and colleagues 2 confirm findings from a survey in a Canadian population by Lal et al. 3 published in 2011 in which chronic abdominal pain was reported as the primary reason for self-medication with Cannabis, especially in patients with a history of abdominal surgery or abdominal pain. One prospective, uncontrolled, observational study reported improved quality of life and reductions of disease activity in patients with IBD who were advised to smoke cigarettes with Cannabis whenever they felt pain. 4 13 patients were included and were provided with 50 g dry Cannabis per month for their on-demand treatment. All patients used the full amount; additional use of Cannabis was not captured. In a recently published, prospective, placebo-controlled, clinical trial by Naftali et al., 5 patients with Crohn's disease received two cigarettes with 11.5 mg tetrahydrocannabinol (THC, the principal psychoactive constituent of Cannabis) per day for 8 weeks. Considerable clinical benefits (such as a decrease in Crohn's disease activity index score) were observed in the THCtreated patients in the secondary analyses, but the primary end point of induction of remission was not achieved. Interestingly, no relevant adverse effects were reported. 4, 5 From these studies we learn that there might be a role for Cannabis in the treatment of IBD, but further information is needed to help select the ideal group of patients in whom Cannabis might be beneficial. Cannabis might indeed have a use for induction or maintenance of remission of Crohn's disease or ulcerative colitis but presently we do not know in which group of patient we should initiate clinical trials. Thus, epidemiological data, such as the results from Ravikoff Allegretti et al., 2 are needed to direct future clinical trials.
What are the mechanisms behind these beneficial effects? The discovery of THC as the psychoactive agent of Cannabis and of the endocannabinoid system paved the way in understanding how Cannabis affects an organism. The endocannabinoid system can be regarded as an endogenous molecular network involved in pain and inflammation, similar to the endovanilloid system or the endogenous opioid system. 1 THC and other cannabinoids bind to cannabinoid receptors (cannabinoid receptor 1 and 2, or CB 1 and CB 2 ), which are expressed in the central and peripheral nervous systems (both CB 1 and CB 2 ), in leuko cytes (CB 2 ), and elsewhere. 6 The 'picture' of the endocannabinoid system was completed when the endogenous ligands of the cannabinoid receptors (endocannabinoids; that is, anand amide and 2-arachidonoylglycerol ) were determined. Figure 1 depicts a basic introduction to the structure of the endocannabinoid system, which consists of the canonical cannabinoid receptors, their endogeneous ligands anandamide and 2-arachidonoylglycerol and their synthesizing and degrading enzymes. Use of Cannabis during IBD probably influences inflammation and pain via cannabinoid and possibly other receptors, 7 thereby influencing downstream regulation within the endocannabinoid system.
The survey findings by Ravikoff Allegretti et al. 2 indicate, however, that Cannabis is particularly helpful in alleviating abdominal pain and nausea, whereas relief of diarrhoea was reported less often. Also, in the Canadian survey, Lal et al. 3 noticed that the number of patients reporting relief of abdominal pain was higher than the number reporting relief of diarrhoea. Both surveys suggest that patients with IBD who have pain could be the best candidates for Cannabis-based treatments. Thus, clinical studies in patients with IBD investigating the effects of Cannabis on pain and on maintenance of remission are warranted, whereas Cannabis might not be the best treatment '' …Cannabis provides benefit in disturbances of the gastrointestinal tract, especially in abdominal pain… '' approach for induction of remission, in which Cannabis was studied recently. 5 The endocannabinoid system is an integral part of the colon and, in patients with active IBD, specific changes support a local regulatory role in intestinal inflammation. 8, 9 Levels of anandamide and its synthesizing enzyme (N-acyl phosphatidylethanolamine phospholipase D) are decreased in patients with ulcerative colitis, whereas production of CB 2 and enzymes responsible for synthesis and degradation of 2-arachidonoylglycero l (diacylglycerol lipase and monoacylglycerol lipase, respectively) are increased compared with healthy controls. 8, 9 The CB 2 receptor and 2-arachidonoylglycero l in the colon therefore might be crucial players in the healing process for IBD in humans. However, we have learned that targeting the endocannabinoid system at specific sites (for example, at the CB 1 or the CB 2 receptor) might have different, potentially even opposing, effects and future clinical trials should therefore use more-specific compounds rather than THC (which acts as a CB 1 and a CB 2 receptor agonist) to specifically characterize influences of the different targets on patients' symptoms. Additionally, from a medical perspective, we should consider more intelligent routes of application for Cannabis because smoking might not only induce lung cancer and other serious illnesses, but, in the context of Crohn's disease, is a well-established i ndependent risk factor for the disease. 10 In summary, the survey by Ravikoff Allegretti et al.
2 strongly suggests that, in patients with IBD, self-medication with Cannabis improves abdominal pain and nausea and is a promising option for an alternative IBD treatment. However, all aforementioned studies have limitations by being uncontrolled or too small. As the authors point out, clinical trials are warranted to determine efficacy, safety and adverse effects of Cannabis-based treatments and this survey study will help to identify the ideal patient selection. With the legalization of medical marijuana in several states of the USA and the observation that almost half of non-Cannabis users in the present survey 2 Figure 1 | Scheme of the endocannabinoid system. The endocannabinoids anandamide and 2-AG are synthesized and released on demand in a paracrine fashion. NAPE needs arachidonic acid as a precursor and is cleaved by a phospholipase D (NAPE-PLD) into anandamide. The key enzyme in synthesizing 2-AG from diacylglycerol is diacylglycerol lipase. Anandamide and 2-AG primarily activate cannabinoid receptors (CB 1 , CB 2 ), but anandamide could also act as a ligand for TRPV1 and GPR55. The existence of an endocannabinoid membrane transporter (EMT) is still controversial. The main enzyme in degrading anandamide is FAAH, whereas 2-AG is degraded by MAGL. EMT, GPR55 and TRPV1 are considered part of the endocannabinoid system. Abbreviations: 2-AG, 2-arachidonoylglycerol; CB, cannabinoid receptor; EMT, endocannabinoid membrane transporter; FAAH, fatty acid amide hydrolase; GPR55, G-protein coupled receptor 55; MAGL, monoacylglycerol lipase; NAPE, N-arachidonoyl phosphatidylethanolamine; NAPE-PLD, N-arachidonoyl phosphatidylethanolamine phospholipase D; TRPV1, transient receptor potential cation channel subfamily V member 1.
